Vistagen Therapeutics (VTGN) Revenue (2011 - 2026)

Vistagen Therapeutics has disclosed Revenue across 10 years of filings, most recently posting $1.5 million for Q2 2026.

• In Q2 2026, Revenue rose 504.92% year-over-year to $1.5 million; the TTM figure through Jun 2026 stood at $2.5 million (up 287.31% YoY), while the FY2026 annual figure was $1.3 million, up 161.11% from the prior year.
• Revenue came in at $1.5 million for Q2 2026 at Vistagen Therapeutics, up from $465000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $1.5 million in Q2 2026 to a low of -$15000.0 in Q1 2025.
• Average Revenue over 5 years is $328061.1, with a median of $239000.0 recorded in 2024.
• Year-over-year, Revenue tumbled 109.15% in 2025 and jumped 3200.0% in 2026.
• Over 5 years, Revenue stood at $180000.0 in 2022, then surged by 128.33% to $411000.0 in 2023, then sank by 43.07% to $234000.0 in 2024, then advanced by 29.49% to $303000.0 in 2025, then soared by 387.13% to $1.5 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $1.5 million in Q2 2026, $465000.0 in Q1 2026, and $303000.0 in Q4 2025.